Literature DB >> 15891770

RNA interference and potential therapeutic applications of short interfering RNAs.

Tom C Karagiannis1, Assam El-Osta.   

Abstract

RNA interference is an endogenous gene-silencing mechanism that involves double-stranded RNA-mediated sequence-specific mRNA degradation. The discovery of this pathway together with the elucidation of the structure and function of short interfering RNAs--the effector molecules of RNA interference--has had an enormous impact on experimental biology. RNA interference technologies are currently the most widely utilized techniques in functional genomic studies. Furthermore, there is an intense research effort aimed at developing short interfering RNAs for therapeutic purposes. A number of proof-of-principle experiments have demonstrated the clinical potential of appropriately designed short interfering RNAs in various diseases including viral infections, cancer and neurodegenerative disorders. Already, in such a short time from their discovery, Acuity Pharmaceuticals (August 2004) and Sirna Therapeutics (September 2004) have filed Investigational New Drug applications with the US FDA to begin clinical trials with modified siRNA molecules in patients with age-related macular degeneration. This review will give a brief overview of the mechanism of RNA interference and applications of the pathway in experimental biology will be discussed. The article will focus on recent developments related to the use of RNA interference technologies in mammalian systems and on potential clinical applications of short interfering RNA-mediated RNA interference.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15891770     DOI: 10.1038/sj.cgt.7700857

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  27 in total

Review 1.  [siRNA in macular degeneration].

Authors:  J Callizo; H T Agostini
Journal:  Ophthalmologe       Date:  2010-11       Impact factor: 1.059

2.  Cationic liposome-nucleic acid complexes: liquid crystal phases with applications in gene therapy.

Authors:  C R Safinya; K K Ewert; Cecília Leal
Journal:  Liq Cryst       Date:  2011-11-22

Review 3.  Lipid-based vectors for siRNA delivery.

Authors:  Shubiao Zhang; Defu Zhi; Leaf Huang
Journal:  J Drug Target       Date:  2012-09-20       Impact factor: 5.121

4.  Cationic liposome-nucleic acid complexes for gene delivery and gene silencing.

Authors:  Cyrus R Safinya; Kai K Ewert; Ramsey N Majzoub; Cecília Leal
Journal:  New J Chem       Date:  2014-11-01       Impact factor: 3.591

5.  Nanogyroids incorporating multivalent lipids: enhanced membrane charge density and pore forming ability for gene silencing.

Authors:  Cecília Leal; Kai K Ewert; Rahau S Shirazi; Nathan F Bouxsein; Cyrus R Safinya
Journal:  Langmuir       Date:  2011-05-25       Impact factor: 3.882

6.  Design and evaluation of histidine-rich amphipathic peptides for siRNA delivery.

Authors:  Bérangère Langlet-Bertin; Christian Leborgne; Daniel Scherman; Burkhard Bechinger; A James Mason; Antoine Kichler
Journal:  Pharm Res       Date:  2010-07       Impact factor: 4.200

7.  Liquid crystal assemblies in biologically inspired systems.

Authors:  Cyrus R Safinya; Joanna Deek; Roy Beck; Jayna B Jones; Cecilia Leal; Kai K Ewert; Youli Li
Journal:  Liq Cryst       Date:  2013-01-01

8.  Silencing of PTK7 in colon cancer cells: caspase-10-dependent apoptosis via mitochondrial pathway.

Authors:  Ling Meng; Kwame Sefah; Meghan B O'Donoghue; Guizhi Zhu; Dihua Shangguan; Afshan Noorali; Yan Chen; Lei Zhou; Weihong Tan
Journal:  PLoS One       Date:  2010-11-16       Impact factor: 3.240

9.  A review of antisense therapeutic interventions for molecular biological targets in asthma.

Authors:  Florin-Dan Popescu; Florica Popescu
Journal:  Biologics       Date:  2007-09

10.  Assessment of allele-specific gene silencing by RNA interference with mutant and wild-type reporter alleles.

Authors:  Yusuke Ohnishi; Katsushi Tokunaga; Kiyotoshi Kaneko; Hirohiko Hohjoh
Journal:  J RNAi Gene Silencing       Date:  2006-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.